Clinical Trial Update: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adding bortezomib after combination chemotherapy, Rituximab, and autologous stem cell transplant in mantle cell lymphoma. Results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Rituximab (rituximab)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-07-31